Alamar Biosciences Expands Alzheimer's Partnership, Adding 86,000 Samples with New Neuro Panel
ALMR sits 49% above its 52-week low of $18.845.
Summary
Alamar Biosciences announced a significant expansion of its partnership with the Alzheimer's Disease Data Initiative and Gates Ventures, adding profiling of 86,000 plasma samples using its new NULISAseq Neuro 220 panel. This builds on the national-scale proteomics initiative launched in mid-July and a June 2025 multi-center effort that profiled over 55,000 samples. The combined dataset, expected to be completed in 2027, will encompass more than 140,000 samples, making it the largest study of neurodegenerative disease. The expansion reflects growing confidence in Alamar's platform and positions the company at the center of a major precision-medicine effort to characterize disease subtypes and trajectories. With a market cap near $1.94 billion and shares trading near a 52-week high, this deal reinforces Alamar's commercial momentum following a 99% revenue increase in Q1 2026.
At the time of this announcement, ALMR was trading at $27.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $18.85 to $29.43. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.